香雪制药(300147) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥526,829,027.86, a decrease of 5.01% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥80,079,610.05, representing an increase of 37.54% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥71,837,255.04, an increase of 36.74% compared to the previous year[3]. - The basic earnings per share for Q3 2023 was -¥0.12, a decrease of 36.84% year-on-year[3]. - The net loss for the period was CNY 646,189,411.75, compared to a loss of CNY 500,116,501.35 in the previous year[18]. - The net profit for the third quarter of 2023 was -131,891,114.43 CNY, compared to -273,923,835.37 CNY in the same period last year, indicating a significant reduction in losses[20]. - The total comprehensive income for the third quarter was -134,661,608.51 CNY, down from -272,224,211.47 CNY year-over-year[21]. - Basic and diluted earnings per share were both -0.22 CNY, an improvement from -0.45 CNY in the previous year[21]. - The company incurred a total operating profit loss of -99,532,121.32 CNY, compared to -233,034,780.16 CNY in the previous year[20]. Assets and Liabilities - The total assets at the end of the reporting period were ¥9,186,898,928.62, down 1.78% from the end of the previous year[4]. - The total assets decreased to CNY 9,186,898,928.62 from CNY 9,353,000,538.98, reflecting a decline of about 1.8%[18]. - The equity attributable to shareholders decreased by 6.19% to ¥2,256,289,646.98 compared to the end of the previous year[4]. - The company's total equity decreased to CNY 2,683,520,158.70 from CNY 2,818,181,767.21, representing a decline of about 4.8%[18]. - Total liabilities decreased slightly to CNY 6,503,378,769.92 from CNY 6,534,818,771.77, a reduction of approximately 0.5%[18]. - Long-term equity investments decreased to RMB 107,081,192.17 from RMB 335,697,564.78, showing a decline of approximately 68%[16]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥191,968,724.70, an increase of 68.33%[3]. - Operating cash flow for the third quarter was 191,968,724.70 CNY, compared to 114,045,921.07 CNY in the same period last year, showing an increase[23]. - The company reported a net cash outflow from investing activities of -40,690,307.09 CNY, compared to a net inflow of 213,701,361.24 CNY in the previous year[23]. - The net cash outflow from financing activities was -195,215,688.37 CNY, compared to -356,294,349.12 CNY in the same period last year[23]. - Cash and cash equivalents at the end of the period were 82,439,616.44 CNY, down from 143,397,370.74 CNY at the end of the previous year[23]. - The company's cash and cash equivalents decreased to RMB 130,958,958.84 from RMB 166,503,309.05 at the beginning of the year[16]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,891[10]. - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., holds 22.59% of the shares, with 149,409,921 shares pledged[10]. Operational Highlights - The company reported a significant increase in asset impairment losses of 611.63% due to increased provisions for long-term investments and inventory[8]. - The company plans to issue shares to raise up to RMB 95,988.40 million, which will not exceed 30% of the total share capital prior to the issuance[12]. - The company agreed to transfer an 18.87% stake in Hubei Tianji Pharmaceutical Co., Ltd. for RMB 200 million, although the shares are currently frozen due to litigation[12]. - The company faces multiple legal executions with total amounts including RMB 330,603,200 and RMB 106,528,608 among others, indicating significant financial liabilities[13][14]. - The company is actively communicating to resolve litigation issues related to its frozen equity stake[12]. - The company reported a total current assets of RMB 1,888,651,236.71 as of September 30, 2023, an increase from RMB 1,693,187,412.38 at the beginning of the year[16]. - Accounts receivable increased to RMB 652,501,295.85 from RMB 599,986,848.05 at the beginning of the year, indicating a growth of approximately 8.7%[16]. - Inventory rose to RMB 504,957,567.51 from RMB 467,074,930.98, reflecting an increase of about 8%[16]. - Research and development expenses were CNY 44,798,579.22, down from CNY 63,508,360.83, indicating a decrease of approximately 29.5%[19]. - The company plans to focus on market expansion and new product development in the upcoming quarters[19]. Audit Status - The company has not undergone an audit for the third quarter report[25].